Browse SLA2

Summary
SymbolSLA2
NameSrc-like-adaptor 2
Aliases FLJ21992; SLAP-2; C20orf156; SLAP2; Src-like adapter protein-2; modulator of antigen receptor signaling; Src ......
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm.; SUBCELLULAR LOCATION: Isoform 1: Cell membrane. Cytoplasmic vesicle. Note=Localized to the plasma membrane and intracellular vesicles, including late endosomal vesicles.; SUBCELLULAR LOCATION: Isoform 2: Cytoplasm Note=May be cytoplasmic and is not localized to membranes.
Domain PF00017 SH2 domain
PF00018 SH3 domain
Function

Adapter protein, which negatively regulates T-cell receptor (TCR) signaling. Inhibits T-cell antigen-receptor induced activation of nuclear factor of activated T-cells. May act by linking signaling proteins such as ZAP70 with CBL, leading to a CBL dependent degradation of signaling proteins.

> Gene Ontology
 
Biological Process GO:0002250 adaptive immune response
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0002757 immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0007159 leukocyte cell-cell adhesion
GO:0019722 calcium-mediated signaling
GO:0019724 B cell mediated immunity
GO:0019932 second-messenger-mediated signaling
GO:0030522 intracellular receptor signaling pathway
GO:0042110 T cell activation
GO:0042113 B cell activation
GO:0050848 regulation of calcium-mediated signaling
GO:0050849 negative regulation of calcium-mediated signaling
GO:0050851 antigen receptor-mediated signaling pathway
GO:0050864 regulation of B cell activation
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050869 negative regulation of B cell activation
GO:0051249 regulation of lymphocyte activation
GO:0051250 negative regulation of lymphocyte activation
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071593 lymphocyte aggregation
GO:1902532 negative regulation of intracellular signal transduction
Molecular Function GO:0005070 SH3/SH2 adaptor activity
GO:0030674 protein binding, bridging
GO:0035591 signaling adaptor activity
GO:0047485 protein N-terminus binding
GO:0060090 binding, bridging
Cellular Component GO:0005770 late endosome
GO:0010008 endosome membrane
GO:0044440 endosomal part
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolSLA2
NameSrc-like-adaptor 2
Aliases FLJ21992; SLAP-2; C20orf156; SLAP2; Src-like adapter protein-2; modulator of antigen receptor signaling; Src ......
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SLA2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSLA2
NameSrc-like-adaptor 2
Aliases FLJ21992; SLAP-2; C20orf156; SLAP2; Src-like adapter protein-2; modulator of antigen receptor signaling; Src ......
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SLA2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSLA2
NameSrc-like-adaptor 2
Aliases FLJ21992; SLAP-2; C20orf156; SLAP2; Src-like adapter protein-2; modulator of antigen receptor signaling; Src ......
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SLA2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1040.779
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0260.969
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.20.724
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3310.558
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5140.68
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1010.946
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.7920.227
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.3970.158
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1940.852
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.640.0419
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0650.373
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1040.628
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SLA2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSLA2
NameSrc-like-adaptor 2
Aliases FLJ21992; SLAP-2; C20orf156; SLAP2; Src-like adapter protein-2; modulator of antigen receptor signaling; Src ......
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLA2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSLA2
NameSrc-like-adaptor 2
Aliases FLJ21992; SLAP-2; C20orf156; SLAP2; Src-like adapter protein-2; modulator of antigen receptor signaling; Src ......
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLA2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLA2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSLA2
NameSrc-like-adaptor 2
Aliases FLJ21992; SLAP-2; C20orf156; SLAP2; Src-like adapter protein-2; modulator of antigen receptor signaling; Src ......
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLA2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSLA2
NameSrc-like-adaptor 2
Aliases FLJ21992; SLAP-2; C20orf156; SLAP2; Src-like adapter protein-2; modulator of antigen receptor signaling; Src ......
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SLA2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSLA2
NameSrc-like-adaptor 2
Aliases FLJ21992; SLAP-2; C20orf156; SLAP2; Src-like adapter protein-2; modulator of antigen receptor signaling; Src ......
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SLA2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSLA2
NameSrc-like-adaptor 2
Aliases FLJ21992; SLAP-2; C20orf156; SLAP2; Src-like adapter protein-2; modulator of antigen receptor signaling; Src ......
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SLA2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.